CDA | Evidence Driven
CDA | Evidence Driven

dimethyl fumarate

Details

Files
Generic Name:
dimethyl fumarate
Project Status:
Active
Therapeutic Area:
Multiple Sclerosis (MS)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0751-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Radiologically Isolated Syndrome (RIS).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received11-Jul-24
Review initiated12-Jul-24
Expert committee meeting (initial)21-Nov-24

Files

Proposed Scope View PDF
Last Updated : October 31, 2024